{"protocolSection": {"identificationModule": {"nctId": "NCT00311155", "orgStudyIdInfo": {"id": "SP-OLM-03-05"}, "secondaryIdInfos": [{"id": "2005-004659-36", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Daiichi Sankyo", "class": "INDUSTRY"}, "briefTitle": "Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension", "officialTitle": "Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension", "acronym": "OLMETREAT"}, "statusModule": {"statusVerifiedDate": "2010-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-03"}, "primaryCompletionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-04-03", "studyFirstSubmitQcDate": "2006-04-03", "studyFirstPostDateStruct": {"date": "2006-04-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-10-12", "resultsFirstSubmitQcDate": "2010-10-12", "resultsFirstPostDateStruct": {"date": "2010-11-10", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2010-10-12", "dispFirstSubmitQcDate": "2010-10-12", "dispFirstPostDateStruct": {"date": "2010-11-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2010-11-23", "lastUpdatePostDateStruct": {"date": "2010-12-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Senior Manager - Study Coordination", "oldOrganization": "Daiichi Sankyo Europe, GmbH"}, "leadSponsor": {"name": "Sankyo Pharma Gmbh", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension."}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["Olmesartan medoxomil", "Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 694, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Olmesartan medoxomil oral tablets for 4 weeks followed by, if necessary:\n\nOlmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets for 8 weeks, followed by, if necessary:\n\nOlmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets + amlodipine oral tablets for 8 weeks", "interventionNames": ["Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary"]}], "interventions": [{"type": "DRUG", "name": "olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary", "description": "Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.", "armGroupLabels": ["1"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.", "description": "For non-diabetic participants the target seated blood pressure goals were: Systolic - \u2264130 mm Hg; Diastolic - \u226485 mm Hg. For diabetic participants the target seated blood pressure goals were: Systolic - \\<130 mm Hg; Diastolic - \\<80 mm Hg.", "timeFrame": "Baseline to \u226420 weeks"}], "secondaryOutcomes": [{"measure": "Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved", "description": "Normalized blood pressure is defined as a mean sitting systolic blood (sBP) pressure at trough of \\<140 mmHg and mean sitting diastolic blood pressure (dBP)of \\<90 mmHg for non-diabetic patients or a mean sitting sBP at trough of \\<130 mmHg and mean sitting dBP \\<80 mmHg for diabetic patients.", "timeFrame": "Baseline to \u226420 weeks"}, {"measure": "Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.", "description": "Diastolic responders were defined as a participant who is a normaliser or has a lowering of the mean sitting diastolic blood pressure of \u226510 mmHg at trough.", "timeFrame": "Baseline to \u226420 weeks"}, {"measure": "Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved", "description": "Systolic responders defined as a participant who is a normaliser or has a lowering of the mean sitting systolic blood pressure of \u226520 mmHg at trough", "timeFrame": "Baseline to \u226420 weeks"}, {"measure": "Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment", "timeFrame": "Baseline to \u226420 weeks"}, {"measure": "Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment", "timeFrame": "Baseline to \u226420 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female patients age greater than or equal to 18 years with mild to moderate hypertension.\n* Pre-treated patients with normal or elevated blood pressure (BP) are eligible to participate if their pre-treatment medication can be withdrawn. At the end of the placebo run-in period sitting systolic BP greater than or equal to 140 and less than 180 mmHg and/or sitting diastolic BP greater than or equal to 90 and less than 110 mmHg at trough.\n\nExclusion Criteria:\n\n* Female patients of childbearing potential must not be pregnant or lactating and must be using adequate contraception.\n* Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the test drug(s), including cardiovascular, renal, pulmonary, hepatic, gastrointestinal, endocrine/metabolic, haematological/oncological, neurological and psychiatric diseases.\n* Patients within the last 6 months having a history of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, heart failure, cerebrovascular accident, or transient ischemic attack.\n* Patients with clinically significant elevations in laboratory values at Screening Visit.\n* Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome.\n* Patients with contraindications for olmesartan medoxomil, hydrochlorothiazide, and/or amlodipine besylate.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Anthony Heagerty, MD", "affiliation": "University of Manchester, Dept. of Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"city": "Fulpmes", "zip": "6166", "country": "Austria", "geoPoint": {"lat": 47.15934, "lon": 11.34961}}, {"facility": "University Klinik, F. Innere Medizin", "city": "Innsbruck", "zip": "6020", "country": "Austria", "geoPoint": {"lat": 47.26266, "lon": 11.39454}}, {"city": "Innsbruck", "zip": "6020", "country": "Austria", "geoPoint": {"lat": 47.26266, "lon": 11.39454}}, {"city": "Kundl", "zip": "6250", "country": "Austria", "geoPoint": {"lat": 47.46667, "lon": 11.98333}}, {"facility": "Diakonissen-Krankenhaus Hospital", "city": "Salzburg-Aigen", "zip": "5026", "country": "Austria"}, {"city": "Salzburg", "zip": "5020", "country": "Austria", "geoPoint": {"lat": 47.79941, "lon": 13.04399}}, {"city": "Bruxelles", "zip": "1080", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"city": "Mechelen", "zip": "2800", "country": "Belgium", "geoPoint": {"lat": 51.02574, "lon": 4.47762}}, {"facility": "Centre Hospitalier du Bois de l'Abbaye et de Hesba, Department of Intensive Care", "city": "Seraing", "zip": "4100", "country": "Belgium", "geoPoint": {"lat": 50.58362, "lon": 5.50115}}, {"facility": "Allgemeen Ziekenhuis Maria-Middelares, Cardiologie, Campus de Pelikaan", "city": "Temse", "zip": "9140", "country": "Belgium", "geoPoint": {"lat": 51.12794, "lon": 4.21372}}, {"city": "Ancerville", "zip": "55170", "country": "France", "geoPoint": {"lat": 48.63574, "lon": 5.02091}}, {"city": "Bourges", "zip": "18000", "country": "France", "geoPoint": {"lat": 47.08333, "lon": 2.4}}, {"city": "Derval", "zip": "44590", "country": "France", "geoPoint": {"lat": 47.66724, "lon": -1.6699}}, {"city": "Grenoble", "zip": "38100", "country": "France", "geoPoint": {"lat": 45.16667, "lon": 5.71667}}, {"city": "Lille", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"city": "Montrevel en Bresse", "zip": "01340", "country": "France", "geoPoint": {"lat": 46.33664, "lon": 5.1234}}, {"city": "Pouilly en Auxois", "zip": "21320", "country": "France", "geoPoint": {"lat": 47.26238, "lon": 4.55583}}, {"city": "Poussan", "zip": "34560", "country": "France", "geoPoint": {"lat": 43.48944, "lon": 3.67083}}, {"city": "Sorcy Saint Martin", "zip": "55190", "country": "France", "geoPoint": {"lat": 48.71367, "lon": 5.63399}}, {"city": "St Aubin des Ch\u00e2teaux", "zip": "44110", "country": "France", "geoPoint": {"lat": 47.72047, "lon": -1.48876}}, {"city": "St Etienne de Montluc", "zip": "44360", "country": "France", "geoPoint": {"lat": 47.2769, "lon": -1.78072}}, {"city": "St Priest", "zip": "69800", "country": "France", "geoPoint": {"lat": 45.69613, "lon": 4.93891}}, {"city": "Strasbourg", "zip": "67000", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"city": "Yerres", "zip": "91330", "country": "France", "geoPoint": {"lat": 48.71785, "lon": 2.49338}}, {"city": "Annweiler", "zip": "76855", "country": "Germany"}, {"city": "Balve", "zip": "58802", "country": "Germany", "geoPoint": {"lat": 51.3315, "lon": 7.86424}}, {"city": "Bammental", "zip": "69245", "country": "Germany", "geoPoint": {"lat": 49.35611, "lon": 8.77944}}, {"facility": "Ev. Krankenhaus Bielefeld, Medizinische Klinik in Bethel - Gilead I", "city": "Bielefeld", "zip": "33617", "country": "Germany", "geoPoint": {"lat": 52.03333, "lon": 8.53333}}, {"facility": "Uniklinik Bonn", "city": "Bonn", "zip": "53111", "country": "Germany", "geoPoint": {"lat": 50.73438, "lon": 7.09549}}, {"city": "Goch", "zip": "47574", "country": "Germany", "geoPoint": {"lat": 51.67873, "lon": 6.15895}}, {"city": "Haag", "zip": "83527", "country": "Germany"}, {"city": "Hamburg", "zip": "20148", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"city": "Heidelberg (Neuenheim)", "zip": "69120", "country": "Germany", "geoPoint": {"lat": 49.40768, "lon": 8.69079}}, {"city": "Heidelberg", "zip": "69115", "country": "Germany", "geoPoint": {"lat": 49.40768, "lon": 8.69079}}, {"city": "M\u00fchldorf / Inn", "zip": "84453", "country": "Germany"}, {"city": "Schwenningen", "zip": "78054", "country": "Germany", "geoPoint": {"lat": 48.65, "lon": 10.65}}, {"city": "VS-Villingen", "zip": "78050", "country": "Germany"}, {"city": "Weyhe", "zip": "28844", "country": "Germany", "geoPoint": {"lat": 52.96667, "lon": 8.66667}}, {"facility": "Ospedale Regina Apostolorum", "city": "Albano Laziale (RM)", "zip": "00041", "country": "Italy"}, {"facility": "Ospedale C.G. Mazzoni", "city": "Ascoli Piceno", "zip": "63100", "country": "Italy", "geoPoint": {"lat": 42.85351, "lon": 13.57395}}, {"facility": "Ospedale Nuovo Cutroni", "city": "Barcellona Pozzo di Gotto (ME)", "zip": "98051", "country": "Italy"}, {"facility": "Casa di Cura \"La Madonnina\"", "city": "Bari", "zip": "70124", "country": "Italy", "geoPoint": {"lat": 41.11148, "lon": 16.8554}}, {"facility": "Ospedale San Sebastiano", "city": "Caserta", "zip": "81100", "country": "Italy", "geoPoint": {"lat": 41.07262, "lon": 14.33231}}, {"facility": "Ospedale Vittorio Emanuele", "city": "Catania", "zip": "95124", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Universit\u00e0 degli Studi \"G. D'Annunzio\"", "city": "Chieti Scalo", "zip": "66013", "country": "Italy"}, {"facility": "Azienda Ospedaliera \"Madonna delle Grazie\"", "city": "Matera", "zip": "75100", "country": "Italy", "geoPoint": {"lat": 40.66599, "lon": 16.60463}}, {"facility": "Ospedale San Paolo", "city": "Milano", "zip": "20142", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Ospedale San Carlo Borromeo", "city": "Milano", "zip": "20153", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Presidio Ospedaliero San Lorenzo", "city": "Palermo", "zip": "90146", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Presidio Ospedaliero di Portogruaro", "city": "Portogruaro (VE)", "zip": "30026", "country": "Italy"}, {"facility": "Azienda Policlinico Universitario a Gestione Diret", "city": "Udine", "zip": "33100", "country": "Italy", "geoPoint": {"lat": 46.0693, "lon": 13.23715}}, {"facility": "Maxima Medisch Centrum", "city": "Eindhoven", "zip": "5631 BM", "country": "Netherlands", "geoPoint": {"lat": 51.44083, "lon": 5.47778}}, {"facility": "H. Elvas", "city": "Elvas", "zip": "7350-954", "country": "Netherlands"}, {"city": "Hertogenbosch", "zip": "5216 GC", "country": "Netherlands", "geoPoint": {"lat": 51.27, "lon": 5.59167}}, {"city": "Hilversum", "zip": "1214 JR", "country": "Netherlands", "geoPoint": {"lat": 52.22333, "lon": 5.17639}}, {"city": "Lieshout", "zip": "5737 CB", "country": "Netherlands", "geoPoint": {"lat": 51.52083, "lon": 5.59478}}, {"city": "Waalwijk", "zip": "5144 CB", "country": "Netherlands", "geoPoint": {"lat": 51.6825, "lon": 5.07083}}, {"facility": "H. Almada", "city": "Almada Almada", "zip": "2801-951", "country": "Portugal"}, {"facility": "Hospital Fernando da Fonseca", "city": "Amadora Amadora", "zip": "2720-276", "country": "Portugal"}, {"facility": "Hospital de. S. Marta", "city": "Lisboa Lisboa", "zip": "1169-024", "country": "Portugal"}, {"facility": "Zentrum Oberdorf", "city": "Affoltern am Albis", "zip": "8910", "country": "Switzerland", "geoPoint": {"lat": 47.27743, "lon": 8.45128}}, {"city": "Bellinzona", "zip": "6500", "country": "Switzerland", "geoPoint": {"lat": 46.19278, "lon": 9.01703}}, {"city": "Gland", "zip": "1196", "country": "Switzerland", "geoPoint": {"lat": 46.42082, "lon": 6.2701}}, {"city": "Petit-Lancy", "zip": "1213", "country": "Switzerland", "geoPoint": {"lat": 46.19647, "lon": 6.11359}}, {"facility": "Praxis Dreispitz", "city": "Zurich", "zip": "8050", "country": "Switzerland", "geoPoint": {"lat": 47.36667, "lon": 8.54999}}, {"facility": "The Atherstone Surgery", "city": "Atherstone", "zip": "CV9 1EU", "country": "United Kingdom", "geoPoint": {"lat": 52.57536, "lon": -1.54693}}, {"facility": "The Medical Centre", "city": "Birmingham", "zip": "B37 7TR", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Waterloo Medical Centre", "city": "Blackpool", "zip": "FY4 3AD", "country": "United Kingdom", "geoPoint": {"lat": 53.81667, "lon": -3.05}}, {"facility": "Rowden Surgery", "city": "Chippenham", "zip": "SN15 2SB", "country": "United Kingdom", "geoPoint": {"lat": 51.46, "lon": -2.12472}}, {"facility": "The Gables Medical Centre", "city": "Coventry", "zip": "CV6 4DD", "country": "United Kingdom", "geoPoint": {"lat": 52.40656, "lon": -1.51217}}, {"facility": "Bridge Medical Centre", "city": "Crawley", "zip": "RH10 1LL", "country": "United Kingdom", "geoPoint": {"lat": 51.11303, "lon": -0.18312}}, {"facility": "Homefield Surgery", "city": "Exeter", "zip": "EX1 2QS", "country": "United Kingdom", "geoPoint": {"lat": 50.7236, "lon": -3.52751}}, {"facility": "Woodside Health Centre", "city": "Glasgow", "zip": "G20 7LR", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Castle Milk Health Centre", "city": "Glasgow", "zip": "G45 9 AW", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Division of Cardiovascular and Endocrine Sciences", "city": "Manchester", "zip": "M13 9NT", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "University of Manchester", "city": "Manchester", "zip": "M13 9WL", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Oakside Surgery", "city": "Plymouth", "zip": "PL5 3PY", "country": "United Kingdom", "geoPoint": {"lat": 50.37153, "lon": -4.14305}}, {"facility": "Norwood Medical Centre", "city": "Sheffield", "zip": "S5 7HD", "country": "United Kingdom", "geoPoint": {"lat": 53.38297, "lon": -1.4659}}, {"facility": "Lovemead Group Practice", "city": "Trowbridge", "zip": "BA14 7EG", "country": "United Kingdom", "geoPoint": {"lat": 51.31889, "lon": -2.20861}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "The trial was conducted between April 2006 and April 2008 in 9 European countries at 58 investigational sites. The countries participating were: Austria, Belgium, France, Germany, Italy, The Netherlands, Portugal, Switzerland, and United Kingdom.", "groups": [{"id": "FG000", "title": "Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed", "description": "Olemesartan 20 mg to start. Hydrochlorothiazide 12.5 mg and then 25 mg was added, if necessary. If blood pressure goal was still not achieved, amlodipine 5 mg and then 10 mg were added, if needed. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "694"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Some participants had multiple reasons for discontinuation", "numSubjects": "601"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "93"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "21"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "17"}]}, {"type": "Did not meet entry criteria", "reasons": [{"groupId": "FG000", "numSubjects": "55"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed", "description": "Olemesartan 20 mg to start. Hydrochlorothiazide 12.5 mg and then 25 mg was added, if necessary. If blood pressure goal was still not achieved, amlodipine 5 mg and then 10 mg were added, if needed. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "694"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.16", "spread": "12.06"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "337"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "357"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Portugal", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}, {"title": "France", "categories": [{"measurements": [{"groupId": "BG000", "value": "121"}]}]}, {"title": "Belgium", "categories": [{"measurements": [{"groupId": "BG000", "value": "94"}]}]}, {"title": "Austria", "categories": [{"measurements": [{"groupId": "BG000", "value": "35"}]}]}, {"title": "Netherlands", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "207"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "141"}]}]}, {"title": "Italy", "categories": [{"measurements": [{"groupId": "BG000", "value": "35"}]}]}, {"title": "Switzerland", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "82.16", "spread": "16.09"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.86", "spread": "4.69"}]}]}]}, {"title": "Ethnicity", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "678"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.", "description": "For non-diabetic participants the target seated blood pressure goals were: Systolic - \u2264130 mm Hg; Diastolic - \u226485 mm Hg. For diabetic participants the target seated blood pressure goals were: Systolic - \\<130 mm Hg; Diastolic - \\<80 mm Hg.", "populationDescription": "691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to \u226420 weeks", "groups": [{"id": "OG000", "title": "Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed", "description": "Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "691"}]}], "classes": [{"title": "Overall N=691", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.8"}]}]}, {"title": "OLM 20 mg N=688", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.3"}]}]}, {"title": "OLM 20 mg+HCTZ 12.5 mg N=580", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.4"}]}]}, {"title": "OLM 20 mg+HCTZ 25 mg N=446", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.2"}]}]}, {"title": "OLM 20 mg+HCTZ 25 mg+AML 5 mg N=296", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.9"}]}]}, {"title": "OLM 20 mg+HCTZ 25 mg+AML 10 mg N=176", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.5"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved", "description": "Normalized blood pressure is defined as a mean sitting systolic blood (sBP) pressure at trough of \\<140 mmHg and mean sitting diastolic blood pressure (dBP)of \\<90 mmHg for non-diabetic patients or a mean sitting sBP at trough of \\<130 mmHg and mean sitting dBP \\<80 mmHg for diabetic patients.", "populationDescription": "691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to \u226420 weeks", "groups": [{"id": "OG000", "title": "Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed", "description": "Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "691"}]}], "classes": [{"title": "Overall N=691", "categories": [{"measurements": [{"groupId": "OG000", "value": "84.5"}]}]}, {"title": "OLM 20 mg N=688", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.7"}]}]}, {"title": "OLM 20 mg + HCTZ 12.5 mg N=580", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.1"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg N=446", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.7"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.9"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.", "description": "Diastolic responders were defined as a participant who is a normaliser or has a lowering of the mean sitting diastolic blood pressure of \u226510 mmHg at trough.", "populationDescription": "691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to \u226420 weeks", "groups": [{"id": "OG000", "title": "Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed", "description": "Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "691"}]}], "classes": [{"title": "Overall N=691", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.3"}]}]}, {"title": "OLM 20 mg N=688", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.6"}]}]}, {"title": "OLM 20 mg + HCTZ 12.5 mg N=580", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.4"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg N=446", "categories": [{"measurements": [{"groupId": "OG000", "value": "48.6"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.4"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.4"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved", "description": "Systolic responders defined as a participant who is a normaliser or has a lowering of the mean sitting systolic blood pressure of \u226520 mmHg at trough", "populationDescription": "691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Baseline to \u226420 weeks", "groups": [{"id": "OG000", "title": "Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed", "description": "Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "691"}]}], "classes": [{"title": "Overall N=691", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.6"}]}]}, {"title": "OLM 20 mg N=688", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.2"}]}]}, {"title": "OLM 20 mg + HCTZ 12.5 mg N=580", "categories": [{"measurements": [{"groupId": "OG000", "value": "49.6"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg N=446", "categories": [{"measurements": [{"groupId": "OG000", "value": "46.6"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.5"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment", "populationDescription": "691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to \u226420 weeks", "groups": [{"id": "OG000", "title": "Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed", "description": "Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "691"}]}], "classes": [{"title": "Overall N=691", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.73", "spread": "7.98"}]}]}, {"title": "OLM 20 mg N=688", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.44", "spread": "7.53"}]}]}, {"title": "OLM 20 mg + HCTZ 12.5 mg N=580", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.15", "spread": "7.54"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg N=446", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.04", "spread": "7.67"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.03", "spread": "8.27"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.47", "spread": "8.86"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment", "populationDescription": "691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to \u226420 weeks", "groups": [{"id": "OG000", "title": "Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed", "description": "Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "691"}]}], "classes": [{"title": "Overall N=691", "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.58", "spread": "13.52"}]}]}, {"title": "OLM 20 mg N=688", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.97", "spread": "11.42"}]}]}, {"title": "OLM 20 mg + HCTZ 12.5 mg N=580", "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.55", "spread": "12.12"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg N=446", "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.51", "spread": "13.14"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296", "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.06", "spread": "13.72"}]}]}, {"title": "OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176", "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.02", "spread": "13.52"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "The time frame was from baseline to up to 20 weeks of treatment", "description": "Safety was addressed in terms of occurrences of adverse envents (AEs), of treatment-emergent AEs, changes in vital signs, ECGs, physical examination findings and laboratory parameters. AEs were documented during the whole study period by spontaneous reports to the investigator or upon questioning by or observations by the investigator.", "eventGroups": [{"id": "EG000", "title": "Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed", "description": "Olemesartan 20 mg to start. Hydrochlorothiazide 12.5 mg and then 25 mg was added, if necessary. If blood pressure goal was still not achieved, amlodipine 5 mg and then 10 mg were added, if needed. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg.", "seriousNumAffected": 7, "seriousNumAtRisk": 694, "otherNumAffected": 293, "otherNumAtRisk": 694}], "seriousEvents": [{"term": "Renal Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 694}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 694}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 694}]}, {"term": "Myocardial infacrtion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 694}]}, {"term": "Lung disorder", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 694}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 694}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 694}]}], "otherEvents": [{"term": "bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 46, "numAtRisk": 694}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 694}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 694}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 694}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 77, "numAtRisk": 694}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 694}]}, {"term": "cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 694}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 694}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 694}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 32, "numAtRisk": 694}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Sr. Director, Regulatory Operations", "organization": "Daiichi Sankyo Pharma Development", "email": "hmkessler@dsi.com", "phone": "732-590-5032"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Spain"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000437965", "term": "Olmesartan"}, {"id": "D000068557", "term": "Olmesartan Medoxomil"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M91890", "name": "Olmesartan", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M273", "name": "Olmesartan Medoxomil", "asFound": "Sleep hygiene", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}